Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial

Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial

Abstract Background Postpartum haemorrhage (PPH) is the leading cause of maternal death worldwide. Tranexamic acid (TA), an antifibrinolytic drug, reduces bleeding and transfusion need in major surgery and trauma. In ongoing PPH following vaginal delivery, a high dose of TA decreases PPH volume and...

Full description

Bibliographic Details
Main Authors: Anne-Sophie Bouthors, Benjamin Hennart, Emmanuelle Jeanpierre, Anne-Sophie Baptiste, Imen Saidi, Elodie Simon, Damien Lannoy, Alain Duhamel, Delphine Allorge, Sophie Susen
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Trials
Subjects:
Postpartum haemorrhage
Caesarean section
Fibrinolysis
Tranexamic acid
Pharmacokinetics
Plasmin
Online Access:http://link.springer.com/article/10.1186/s13063-017-2420-7

Internet

http://link.springer.com/article/10.1186/s13063-017-2420-7

Similar Items